Keenova's Strong Fourth Quarter Performance Reflects Brand Transition Success
Keenova Therapeutics plc has recently released its unaudited financial results for the fourth quarter of 2025, revealing a remarkable performance that surpasses previous expectations. This quarterly success is primarily attributed to the increased strength of its flagship products: Acthar® Gel and XIAFLEX®.
In Q4 of 2025, Keenova reported net sales from continuing operations of $543.0 million. This figure represents an impressive increase of $277.3 million compared to the same timeframe in 2024. The significant growth is largely fueled by a 48% increase in sales of Acthar Gel, which amounted to $205.6 million. Additionally, XIAFLEX contributed $156.5 million to the net sales, showcasing the brand's expanding market penetration.
Despite these commendable revenues, Keenova is expecting a loss from continuing operations between $105.0 and $115.0 million. This increase in losses compared to the previous year's income of $566.4 million is attributed to various transaction-related costs and fair value adjustments resulting from the company's strategic merger with Endo LP and the subsequent spin-off of Par Health.
The CEO of Keenova, Siggi Olafsson, articulated the transformative changes within the company throughout 2025. The firm has made substantial progress in its evolution into a dedicated branded therapeutics organization. The successful launch of SelfJect™, a delivery system for Acthar, and the continuing expansion of market awareness have also contributed to the quarter's success. Encouraging performance in XIAFLEX's development led to advancements in clinical trials, particularly for a hammer toe program that is set to proceed into Phase 3 following a successful proof-of-concept study.
Looking ahead, Keenova has revised its financial guidance for full-year 2026, projecting net sales between $1.94 billion and $2.00 billion, with an adjusted EBITDA expected to range from $730 million to $760 million. This forecast takes into account the anticipated synergies from its recent merger with Endo as well.
In line with its merger synergies, Keenova achieved approximately $13 million in pre-tax synergies during the fourth quarter. The firm expects these to escalate to about $100 million in 2026, as it strives to meet its goal of $150 million in annual synergies by the end of the merger's third year.
Keenova is also exploring further opportunities for profit enhancement through targeted acquisitions and potential divestitures, including the valuable PERCOCET® business, expected to generate significant revenue.
With a firm foundation established through its innovative therapies and robust market position, Keenova remains optimistic about its capability to address the needs of patients living with rare or unaddressed health conditions. Through strategic initiatives and product expansion, the company is well-equipped for sustainable long-term growth.
As Keenova prepares for a possible listing on the New York Stock Exchange in the latter half of 2026, its strong performance in Q4 indicates a promising future driven by its commitment to improving the lives of those facing rare ailments. The momentum gained through innovative products and thoughtful management contributes to a hopeful outlook for investors and patients alike. The upcoming conference call on March 31, 2026, is anticipated to provide further insights into the company’s operational plans and strategic direction going forward.
Fourth Quarter Highlights
In Q4 of 2025, Keenova reported net sales from continuing operations of $543.0 million. This figure represents an impressive increase of $277.3 million compared to the same timeframe in 2024. The significant growth is largely fueled by a 48% increase in sales of Acthar Gel, which amounted to $205.6 million. Additionally, XIAFLEX contributed $156.5 million to the net sales, showcasing the brand's expanding market penetration.
Despite these commendable revenues, Keenova is expecting a loss from continuing operations between $105.0 and $115.0 million. This increase in losses compared to the previous year's income of $566.4 million is attributed to various transaction-related costs and fair value adjustments resulting from the company's strategic merger with Endo LP and the subsequent spin-off of Par Health.
Transformation and Future Outlook
The CEO of Keenova, Siggi Olafsson, articulated the transformative changes within the company throughout 2025. The firm has made substantial progress in its evolution into a dedicated branded therapeutics organization. The successful launch of SelfJect™, a delivery system for Acthar, and the continuing expansion of market awareness have also contributed to the quarter's success. Encouraging performance in XIAFLEX's development led to advancements in clinical trials, particularly for a hammer toe program that is set to proceed into Phase 3 following a successful proof-of-concept study.
Looking ahead, Keenova has revised its financial guidance for full-year 2026, projecting net sales between $1.94 billion and $2.00 billion, with an adjusted EBITDA expected to range from $730 million to $760 million. This forecast takes into account the anticipated synergies from its recent merger with Endo as well.
Merger Synergies and Growth Initiatives
In line with its merger synergies, Keenova achieved approximately $13 million in pre-tax synergies during the fourth quarter. The firm expects these to escalate to about $100 million in 2026, as it strives to meet its goal of $150 million in annual synergies by the end of the merger's third year.
Keenova is also exploring further opportunities for profit enhancement through targeted acquisitions and potential divestitures, including the valuable PERCOCET® business, expected to generate significant revenue.
With a firm foundation established through its innovative therapies and robust market position, Keenova remains optimistic about its capability to address the needs of patients living with rare or unaddressed health conditions. Through strategic initiatives and product expansion, the company is well-equipped for sustainable long-term growth.
Conclusion
As Keenova prepares for a possible listing on the New York Stock Exchange in the latter half of 2026, its strong performance in Q4 indicates a promising future driven by its commitment to improving the lives of those facing rare ailments. The momentum gained through innovative products and thoughtful management contributes to a hopeful outlook for investors and patients alike. The upcoming conference call on March 31, 2026, is anticipated to provide further insights into the company’s operational plans and strategic direction going forward.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.